The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Primary Systemic (AL) Amyloidosis

In brief

This is a multi-center, international, randomized, double-blind, placebo-controlled, two-arm efficacy and safety study in subjects newly diagnosed with AL amyloidosis. Subjects will remain on-study until study completion, which will occur when all primary endpoint events (all-cause mortality or cardiac hospitalizations) have been reached.

Key facts

Study ID
NCT02312206
Run by
Prothena Biosciences Ltd.
People needed
260
Starts
2015-02-01
Expected to finish
2018-05-01
Last updated by the study team
2023-11-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.